ARS Pharmaceuticals (NASDAQ:SPRY) Insider Eric Karas Sells 25,000 Shares of Stock

Posted by Brian Himes on Jun 13th, 2026

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Eric Karas sold 25,000 shares of ARS Pharmaceuticals stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 12,176 shares in the company, valued at $121,760. This trade represents a 67.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ARS Pharmaceuticals Trading Up 1.8%

Shares of SPRY stock opened at $9.76 on Friday. ARS Pharmaceuticals, Inc. has a 12-month low of $6.66 and a 12-month high of $18.90. The company has a current ratio of 4.94, a quick ratio of 4.77 and a debt-to-equity ratio of 2.79. The stock’s 50-day moving average price is $8.42 and its 200-day moving average price is $9.33. The stock has a market capitalization of $969.17 million, a price-to-earnings ratio of -4.86 and a beta of 0.94.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%.The company had revenue of $22.68 million for the quarter, compared to the consensus estimate of $22.20 million. Equities research analysts predict that ARS Pharmaceuticals, Inc. will post -1.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SPRY has been the topic of several analyst reports. Cantor Fitzgerald boosted their price objective on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. Wall Street Zen raised ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Northland Securities initiated coverage on ARS Pharmaceuticals in a research note on Thursday, April 9th. They set an “outperform” rating and a $25.00 price objective on the stock. Finally, Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.60.

Get Our Latest Stock Analysis on SPRY

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SPRY. Rubric Capital Management LP grew its stake in shares of ARS Pharmaceuticals by 247.5% during the third quarter. Rubric Capital Management LP now owns 4,500,000 shares of the company’s stock valued at $45,225,000 after buying an additional 3,205,122 shares during the last quarter. Millennium Management LLC bought a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $36,912,000. Adage Capital Partners GP L.L.C. bought a new position in shares of ARS Pharmaceuticals during the second quarter valued at approximately $30,154,000. Casdin Capital LLC bought a new position in shares of ARS Pharmaceuticals during the third quarter valued at approximately $16,080,000. Finally, Aberdeen Group plc grew its stake in shares of ARS Pharmaceuticals by 106.1% during the third quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock valued at $31,125,000 after buying an additional 1,594,447 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.